Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 12/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220904 | 0.81 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1708588 | 0.80 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL14347170 | 0.80 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL221703 | 0.79 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL221596 | 0.79 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL13811093 | 0.79 | RAB9A (0.38) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282237 | 0.78 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL18365218 | 0.77 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL1282532 | 0.76 | ABL1 (0.51) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL15260120 | 0.76 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| EP-2625178-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | Biota Europe Ltd (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| WO-2012045124-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | BIOTA EUROPE LTD (GB) | 2012-04-12 | — | — | WO | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20100311766-A1 | ANTIBACTERIAL COMPOSITIONS | BIOTA EUROPE LTD (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311766-A1 | ANTIBACTERIAL COMPOSITIONS | BIOTA EUROPE LTD (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311766-A1 | ANTIBACTERIAL COMPOSITIONS | BIOTA EUROPE LTD (GB) | 2010-12-09 | — | — | US | disclosed |
| WO-2009074810-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | NPC1 1032/4885RAB9A 915/4885SMN1; SMN2 4065/4885 |
| US-20120004221-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | NPC1 2581/4885RAB9A 3590/4885SMN1; SMN2 3141/4885 |
| US-20100311766-A1 | ANTIBACTERIAL COMPOSITIONS | C5, AGK, CYCS | NPC1 3590/4885RAB9A 1924/4885SMN1; SMN2 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.